Organogenesis
This article was originally published in The Gray Sheet
Executive Summary
Forms subsidiary ECM Pharma to "develop medical devices and pharmaceutically active compounds based upon natural components of the extracellular matrix," the firm reports. ECM Pharma's initial plans are to "supply cell-produced human collagen...for evaluation, testing, and ultimate use in medical devices, drug delivery, research, and manufacturing." The subsidiary, based in Organogenesis' Canton, Massachusetts facility, "expects to license issued and pending" patent applications for "production of cultured human collagen" and "the assembly of collagen into various forms and shapes"
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.